A life sciences renaissance: 125th peer-reviewed publication enabled by xCELLigence System

Penzberg, Germany, 23. März 2011

To date, more than 125 peer-reviewed studies using Roche’s (SIX: RO, ROG; OTCQX: RHHBY) xCELLigence System have been published, spanning a diverse group of applications, including cell invasion and migration of cancer cells (1), receptor activity assays (2), compound induced cytotoxicity (3), antibody-dependent cellular cytotoxicity (4), virus-mediated cytopathogenicity (5) and others (6). The fields of research included toxicology, drug discovery, receptor biology, cancer research, inflammation, neurobiology, among others and are complemented by numerous review articles on the current uses and future potential of the xCELLigence System.

The 125th study (7), entitled “Differential roles of Src in transforming growth factor-β regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells,” was published in March 2011 in the International Journal of Oncology. The authors Hendrik Ungefroren, Susanne Sebens, Stephanie Groth, Frank Gieseler and Fred Fändrich explored the potential role of the non-receptor tyrosine kinase Src in TGF-β1-mediated cellular responses using RNA and dominant-negative interference to block Src expression and function, respectively. For real-time measurement of cell migration, they used the xCELLigence RTCA DP Instrument from Roche.

The first xCELLigence System, the RTCA SP Instrument, was launched in mid-2008. The speed with which researchers using the xCELLigence System have been able to publish their discoveries demonstrates the high-quality of this analysis system, its ease of use and the reliability of the results.

“The xCELLigence System enables researchers to tackle innovative research, access diverse applications – and publish faster. Reaching 125 peer-reviewed publications so quickly is a testament to the widespread field of applications for which the system has been adopted,” explained Ruedi Stoffel, Life Cycle Leader Cellular Analysis at Roche Applied Science. Across all fields of cell science we have seen a fast growing number of papers in the last two years.”

The xCELLigence System monitors cellular events in real-time without the incorporation of labels. The system measures electrical impedance across interdigitated micro-electrodes integrated on the bottom of a tissue culture E-Plate. The impedance measurement provides quantitative information about the biological status of the cells, including cell number, viability and morphology. A wide range of cell-based assays for both high-throughput screening and research laboratory environments can be performed on the xCELLigence System.

For additional information, please visit http://www.xcelligence.roche.com

(1) Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Greiner M, Kreutzer B, Jung V, Grobholz R, Hasenfus A, Stöhr RF, Tornillo L, Dudek J, Stöckle M, Unteregger G, Kamradt J, Wullich B, Zimmermann R. Int J Cancer. 2010 Jul 28. [Epub ahead of print].

(2) Potent Agonists of the Protease Activated Receptor 2 (PAR(2)). Boitano S, Flynn AN, Schulz SM, Hoffman J, Price TJ, Vagner J. J Med Chem. 2011 Feb 4. [Epub ahead of print].

(3) Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. Fecker LF, Rückert S, Kurbanov BM, Schmude M, Stockfleth E, Fechner H, Eberle J. Hum Gene Ther. 2011 Feb 16. [Epub ahead of print].

(4) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, Vaughn JP. Cancer Immunol Immunother. 2009 Apr 2.

(5) Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. Hristov G, Krämer M, Li J, El-Andaloussi N, Mora R, Daeffler L, Zentgraf H, Rommelaere J, Marchini A. J Virol. 2010 Jun;84(12):5909-22.

(6) Validation of xCELLigence real-time cell analyzer to assess compatibility in xenotransplantation with pig-to-baboon model. Quereda JJ, Martínez-Alarcón L, Mendoça L, Majado MJ, Herrero-Medrano JM, Pallarés FJ, Ríos A, Ramírez P, Muñoz A, Ramis G. Transplant Proc. 2010 Oct; 42(8):3239-43.

(7) Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells. Ungefroren H, Sebens S, Groth S, Gieseler F, Faendrich F. Int J Oncol. 2011 Mar; 38(3):797-805. Epub 2011 Jan 11.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

XCELLIGENCE is a trademark of Roche.
E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US.
Other brands or product names are trademarks of their respective holders.